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Abstract: Multiparametric analyses of phospho-protein activation in patients with acute myeloid 
leukemia (AML) offers a quantitative measure to monitor the activity of novel intracellular kinase 
(IK) inhibitors. As recent clinical investigation with FMS-like tyrosine-3 inhibitors demonstrated, 
targeting IK with selective inhibitors can have a modest clinical benefit. Because multiple IKs 
are active in patients with AML, multikinase inhibitors may provide the necessary inhibition 
profile to achieve a more sustained clinical benefit. We here describe a method of assessing the 
activation of several IKs by flow cytometry. In 40 different samples of patients with AML we 
observed hyper-activated phospho-proteins at baseline, which is modestly increased by adding 
stem cell factor to AML cells. Finally, AML cells had a significantly different phospho-protein 
profile compared with cells of the lymphocyte gate. In conclusion, our method offers a way 
to determine the activation status of multiple kinases in AML and hence is a reliable assay to 
evaluate the pharmacodynamic activity of novel multikinase inhibitors.
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Introduction
Relapsed acute myeloid leukemia (AML) remains a disease with poor prognosis in 
which new therapies are needed.1 Targeting intracellular kinases (IK) responsible for 
critical signal transduction pathways in AML represents a novel approach of developing 
agents to treat AML.2 Clinically, activated or phosphorylated IKs are associated with 
prognosis in patients with AML.3 One important IK in AML is the FMS-like tyrosine 
kinase 3 (FLT 3). Various FLT3 inhibitors have been developed to inhibit wildtype 
or mutated FLT3.4–11 However, the clinical benefit of selective FLT3 inhibitors has 
been modest, perhaps because the single pathway inhibition may not be sufficient 
to affect the AML progression. Based on the observation that selective inhibition of 
FLT3 indirectly also modulates other IKs such as ERK,8,12 novel IK inhibitors, such 
as KW2449,13 are being developed to target multiple IKs. For the clinical develop-
ment of such multikinase inhibitors, it is essential to monitor sequentially the activity 
of IKs simultaneously.
One way to determine the status of IK activation and subsequent alteration by IK 
inhibitors, is based on the use of multiparametric flow cytometric analysis.14,15 This 
approach of analyzing multiple phosphorylated proteins in AML requires a sophisti-
cated isolation, fixation and permeabilitization procedure followed by a rigorous flow 
cytometric analysis. Analyses protocols have been presented for the IK inhibitor sorafenib 
in AML patients,16 but such assessments are limited to specialized laboratories.17 Cancer Management and Research 2009:1 50
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Previous studies have suggested that assessing extracellular 
signaling-regulated kinase (pERK 1/2) may reflect anti-
leukemia activity of sorafenib.16 Given the advances in flow 
cytometry, the role of IKs in AML pathology and the rapid 
development of several IK inhibitors, we here present a multi-
parametric flow cytometry assay, which can be conducted 
at routine clinical pathology laboratories. Our interest was 
focused on the assessment of pERK, pcKIT (stem cell factor 
receptor or CD117), pFLT3, pY100 (pan receptor tyrosine 
kinase marker), ribosomal protein pS6 (ribosomal protein 
involved in downstream signaling events of several receptor 
tyrosine kinases) and pAKT, because these IKs are generally 
activated in some or most AML cells.3,16 Thus, our assay may 
be used to monitor sequentially the activity of multi-targeted 
IK inhibitors in AML patients.
Materials and methods
AML sample preparation (materials)
In compliance with United States (US) Health Insurance 
Portability and Accountability Act (HIPAA) guidelines, 
we obtained bone marrow samples from 40 patients with 
relapsed AML from different hematology practices in 
the US. All samples were obtained as discarded material 
(during the course of 2006) along with patient specific pheno-
typing results, from the Esoterix Oncology diagnostic lab 
(Austin, TX) after all diagnostic testing had been performed 
and patient information had been de-identified. Demographic 
information noted on requisition forms was used to charac-
terize the origin of the bone marrow samples. In each case, 
automated cell counts were obtained and samples were 
placed in a 37 °C/5% CO2 incubator for one hour prior to 
processing to allow enzyme activity and cellular processes to 
stabilize. The testing for each sample was obtained for basal 
levels and an additional aliquot was stimulated with 10 ng/ml 
of stem cell factor (R&D Systems, Minneapolis, MN) for 
exactly 15 minutes and immediately fixed/permeabilized 
per US Patent #7326577. All samples were then placed at 
2–8 °C overnight to be stained for phosphorylated proteins 
the following day as indicated below.
Antibodies (materials)
All antibodies to phosphorylated proteins were obtained 
from Cell Signaling Technology (CST) (Danvers, MA). 
Antibody specificity titrations were performed prior to use of 
the antibodies based on rested and stimulated conditions to 
obtain the saturating concentrations for each antibody. Thus, 
the antibodies were used per 1–2 × 106 cells. The specific 
antibodies for this study were: phospho-FLT3 (CD135) 
(Y591)-Alexa Fluor 488 (CST #3459); phospho-c-KIT 
(CD117) (Y719) (CST#3391L); phospho-p44/42 extracel-
lular signaling-regulated kinase 1/2 (ERK1/2) (T202/Y204) 
Alexa Fluor 647 (CST#4375); phospho-AKT (S473)-Alexa 
Fluor 647 (CST2337); phospho-Tyrosine-Y100-Alexa Fluor 
488 (CST 9414); phospho-S6 Ribosomal Protein (S235/236)-
Alexa Fluor 647 (CST, Esoterix custom conjugate). The 
surface antibodies used for the study were CD11b-Alexa 
Fluor 700 (Esoterix custom conjugate; Beckman Coulter, 
Miami, FL); CD34-Biotin (Invitrogen, Carlsbad, CA) and 
CD45-PE (Immunotech; Beckman Coulter). The isotype 
controls used for the phospho-proteins were matched to the 
primary antibodies at the identical concentrations used in 
the assay. The CD34-Biotin was developed post fixation 
using streptavidin QDOT 605 (Invitrogen) and the phospho 
c-KIT was developed using a goat anti rabbit Alexa Fluor 
488 (both used at 1 µg per staining reaction). In all cases, 
the staining reactions were carried out in 50 µl total volumes 
in phosphate-buffered saline (PBS) with 3.4% bovine serum 
albumin (BSA).
Staining of AML samples for surface  
and phosphorylated proteins
The samples were surface stained with the CD34 and CD11b 
antibodies for 20 minutes. If cells were chosen for ex vivo 
stimulation, they were immediately stimulated with SCF and 
fixed/permeabilized as indicated above. The cells were spun 
out of fixative and washed twice in PBS + 2% NCS. Respec-
tive phospho antibodies as listed below were added to the 
cell pellet and allowed to incubate for one hour at ambient 
temperature in the dark. The excess antibody was removed 
by washing the cells twice in 2 ml of PBS-2% NCS with 
10 minute soaks between each centrifugation. The following 
combinations were used for each donor: Tube (1) p-cKIT/
p44/42/ERK1/2-AF647; Tube (2) pFLT3-AF488/pS6-
Ribosomal Protein-AF647; Tube (3) pY100-AF488/pAKT-
AF647; Tube (4) isotype Alexa 488/isotype Alexa 647. The 
secondary antibodies were added to the appropriate tubes in 
conjunction with CD45-PE in all tubes and incubated for an 
additional 20 minutes. The excess antibody was removed 
using same wash sequence as listed above. Finally, the cells 
were re-suspended in 400 µl of PBS-2% NCS final volume 
and 100,000 intact events were collected per tube during flow 
cytometry assessments.
Cytometer information
Flow cytometry was performed on a Beckman Coulter FC500 
with custom filter sets designed to optimize the collection of Cancer Management and Research 2009:1 51
Phospho-protein expression in AML patients Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Alexa 647 and Alexa 700 signals. The instrument was set 
up using QC3 beads (Bangs Laboratories, Fishers, IN) for 
the daily monitoring of instrument performance within an 
accepted “window of analysis”. Full spectrum fluorescent 
calibration particles (Spherotech, Lake Forest, IL) were also 
run with each assay to determine the molecules of equivalent 
fluorescence (MEFL) of the phospho-proteins in a methodol-
ogy that has been described in detail.18
Sample analysis
Each sample was analyzed using a direct data exchange (DDE) 
link between WinList 6.0 (Verity Software House, Topsham, 
MA) and Mircosoft Excel (Microsoft, Redmond, WA). All 
data gating, displaying, and processing were conducted in 
WinList. The pattern recognition of the marrow elements 
was by eye and experience based on known CD45/SSC 
patterns. The MEFL of the phospho-proteins was measured 
in the “blast” population as determined by CD45/SSC 
and/or CD34+, CD11b- staining. In samples that contained 
more than one phenotypic clone of “blasts”, each clone was 
analyzed individually for phospho-protein expression. The 
SCF stimulated levels were compared to the unstimulated 
levels in each population.
Statistical analysis
AML phospho-protein expression was analyzed using a 
mixed effect ANOVA model using the REML method to esti-
mate covariance parameters. A variance components structure 
was used for the covariance matrix. For normalized untreated 
AML, the SCF-treated AML, and the ratio of untreated 
AML to lymphocyte responses the model used the follow-
ing terms: AML FAB Classification, Patient nested within 
AML FAB Classification (random factor), IK, phenotype, 
IK*phenotype, AML FAB Classification*IK, and AML FAB 
Classification*phenotype. Pairwise comparisons were made 
using the LSMEANS and pdiff options in SAS Proc Mixed 
(SAS Institute Inc. Cary, NC). A Fisher’s LSD approach was 
used to approximately control the experiment-wise type I 
error rate. Also, not all pairwise comparisons were of inter-
est. For significant interaction model terms, the slice option 
was used in SAS to further protect the experimentwise error 
rate. Only statistically significant slices were followed up with 
further pairwise comparisons. The data were analyzed using 
JMP ver. 6.0.2 and SAS ver. 9.1 (SAS Institute, Inc.).
Results
We obtained bone marrow samples from 40 patients with 
relapsed AML to test a novel technique of determining 
phospho-protein expression in AML blasts and to profile 
AML blast cells based on their ability to express specific 
phospho-proteins. All samples were received from different 
hematology practices in the United States, and were evalu-
ated as part of routine hematological evaluation (Table 1). 
We used samples from relapsed AML patients based on the 
assumption that AML blasts in advanced disease will show 
increased phosphorylation levels.16 From the 40 samples, 
19 (47%) had not been classified based on the FAB AML 
classification, of which eight patients had recurrent AML 
(8/19; 42%). In addition to AML samples with no clear 
FAB classification, there were samples from six M1 and M4 
AML patients, respectively (each 6/40; 15%). For M2, M3, 
and M5 AML there were each three samples (3/40; 7%). 
In 5/40 (12%) patients the bone marrow showed less than 
20% blast cells.
Based on this randomly collected material from patients 
with AML, we evaluated the phospho-protein levels with-
out and with SCF ex vivo stimulation. After gating cells on 
forward scatter (FS) vs. side scatter (SS), cells were gated 
based on CD45, CD11b and CD34 expression prior to ana-
lyzing the phospho-protein expression of pERK, pc-KIT, 
pAKT, pY100, pFLT3, and pS6 (Figures 1 and 2). Based 
on the surface marker expression, we categorized the cell 
population in the following groups: (a) AML phenotype 1, 
(b) phenotype 2 and (c) lymphocytes. AML phenotype 1 was 
characterized by CD34hi/CD45low/CD11b- surface expression 
(red gate in Figures 2A,B) consistent with an “immature-
like” cell population. AML phenotype 2 was characterized 
by CD34low/CD45hi/CD11b+ surface expression (green gate 
in Figures 2A, B) which is characteristic for “mature-like” 
cells. Most samples in this study were AML Phenotype 1 cells 
(Table 2). Compared to the lymphocytes, both phenotype 1 
and 2 AML cells showed high phospho-protein expression 
(Figures 2–4). Ex vivo stimulation with SCF increased levels 
of phosphorylation in both phenotypes of AML, but not in 
lymphocytes (Figures 2C–F). Hence, lymphocytes can serve 
as negative control for assessing the effect of SCF-induced 
phosphorylation of IKs in AML cells.
We then investigated whether phenotype 1/2 or cells 
based on the FAB AML classification were associated with a 
particular phospho-protein expression pattern (Figures 3, 4). 
AML cells were immediately assessed after receipt in the 
clinical pathology lab and without any additional in vitro 
stimulation (basal condition) (Figure 3). pFLT3, pS6, pY100 
and pcKIT were increased compared with p-AKT and p-ERK 
(Figure 3, Panel A and B). Phospho-protein expression 
between phenotype 1 and 2 was similar with statistical Cancer Management and Research 2009:1 52
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differences observed between phenotype 1 and 2 for p-FLT3 
(p = 0.0034) and p-Y100 (p = 0.0041) (data not shown). There 
were also statistical differences observed in phospho-protein 
expression for p-FLT3 and p-Y100 among the AML FAB 
classification (Figure 3C). For these two IKs the M3 AML 
classification showed lower phospho-protein expression 
compared to the other subtypes (Figure 3, Panel C).
When the same AML cells were stimulated with 
SCF (Figure 4), the overall phospho-protein expres-
sion was modestly increased compared to un-stimulated 
cells (Table 3). In particular, pAKT, pS6 and pERK were 
significantly increased after stimulation with SCF compared 
to unstimulated cells (Table 3). Phospho-protein expres-
sion between phenotype 1 and 2 were similar to the overall 
pattern, but after stimulation there were statistical differ-
ences between phenotype for p-ERK (p = 0.0345), p-FLT3 
(p = 0.0047), p-Y100 (p = 0.0095), and Survivin (p = 0.0186) 
(data not shown). Further, there were statistical differences 
observed in the phospho-protein expression for p-FLT3 
among the AML FAB classification. For p-FLT3, the M3 
AML classification was statistically lower than all other FAB 
classifications (p  0.05) (Figure 4C).
In contrast to phospho-protein expression of IKs, survivin 
belongs to a different group of intracellular signaling proteins 
and its overexpression has been associated with poor differ-
entiation and prognosis in AML.19–21 Hence, the survivin 
expression served as an additional control in this study to 
differentiate between activation pattern of phospho-proteins 
and constitutive intracellular activation. Consistent with the 
previous studies, survivin expression was present in all AML 
cell and its expression did not increase after SCF stimulation 
(Figures 3 and 4).
Finally, we also compared the phospho-protein expres-
sion to the cells in the lymphocyte gate (Figure 5). We found 
that all phospho-protein levels are elevated and statistically 
different when compared to the cells in the lymphocyte gate. 
All IK signals increased by greater than 2-fold compared to 
lymphocytes with the greatest differences observed for pAKT 
(8-fold) and pERK (6-fold) (Figure 5A). This difference is 
remarkable because both phospho-proteins were low at the 
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basal level for all the AML cells. Comparison to cells in the 
lymphocyte gate was even more useful to differentiate the 
phospho-protein expression pattern between phenotype 1 and 
2 (Figure 5 B). Compared to the cells in the lymphocyte gate, 
phenotype 2 AML cells had higher phospho-protein levels 
than phenotype 1 with statistical differences observed for 
p-FLT3 (p = 0.0005) and p-Y100 (p = 0.0005) (Figure 5B). 
For survivin, phenotype 1 was statistically lower than phe-
notype 2 (p = 0.0301). With regards to the FAB classifica-
tion, M4 (7-fold, p = 0.0001) and M5 (12-fold, p = 0.0001) 
subtypes showed the greatest activation compared to the cells 
in the lymphocyte gate (Table 4). Thus, the comparison to 
cells in the lymphocyte gate appears to increase the resolu-
tion to differentiate phospho-protein expression in AML cells 
from other cell types present in the bone marrow.
Discussion
In AML, Western Blotting has been used to assess the 
inhibitory activity of IK inhibitors, such as sunitinib,8 and 
recently multiparametric analysis using flow cytometry 
has been applied to monitor phospho-protein changes after 
administration of IK inhibitors in patients with AML.16,22 
The advantages of using flow cytometric analysis lie in its 
ability to provide quantitative assessment of cellular events 
and to determine pharmacodynamic effects in nearly real-
time. In the present study, we evaluated the application of 
an assay to monitor phospho-protein changes in the setting 
of a clinical diagnostic pathology laboratory. The present 
assay is part of developing tools to monitor the pharma-
codynamic changes induced by IK inhibitors in patients 
with AML. Thus, the validation comprised three important 
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Table 2 Surface marker expression of AML cells allows definition 
of two categories (Phenotype 1 and 2)
Phenotype of  
AML cells
Characteristics  
defined by CD
N (samples) 
Phenotype 1 CD34+/CD45low/CD11b- 40
Phenotype 2 CD34-/CD45hi/mid/CD11b+ 24
Notes: For Phenotype 1, 29 out of 40 samples were CD34+.  For remaining 11 samples, 
CD34 was negative with concomitant CD45 staining being low. For Phenotype 2, 22 
out of 24 samples were CD34-.   All 24 samples from Phenotype 2 showed mid to 
high levels of CD45 staining.Cancer Management and Research 2009:1 56
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development steps: first, the development of appropriate 
gating protocols to allow for simultaneous evaluation of 
various phospho-protein changes in patient-derived AML 
cells; second, a profile of phospho-protein expression across 
various types of AML cells (including those defined by the 
AML FAB classification); and thirdly, the differentiation of 
phospho-protein events from other cell population present 
in the bone marrow.
The present protocol allows the assessment of 6 different 
phospho-proteins in AML cells, including those that have 
been recently targeted by IK inhibitors (Figures 1 and 2). 
To our knowledge this is the first time that multiparametric 
assessment of both basal and stimulated levels of 6 different 
phospho-proteins has been reported. Setting up the appropri-
ate gates involved the standard approach of defining the cell 
population based on size (FS vs SS), followed by the subse-
quent gating on surface marker expression defined by CD45, 
CD34 and CD11b. This generally is sufficient to gate on the 
most relevant AML population with myeloid characteristics, 
including “immature”- and “mature”-like phenotypes. A third 
population, which serves as a control, is the cell population 
in the lymphocyte gate, which is characterized by CD45 and 
SSlow expression. Our categories of phenotype 1 (“immature”) 
and 2 (“mature”) were made to reduce the complexity of the 
sample and to investigate whether AML cells with immature 
phenotype had a higher phospho-protein expression pat-
tern than those with a more mature phenotype. Although, 
the “immature” AML cells had a higher phospho-protein 
expression than those with a more “mature-like” pattern, 
the numbers were too skewed towards the phenotype 1 to 
estimate a possible correlation of phenotype 1/2 and a par-
ticular phospho-protein profile. The third gated population 
had the characteristics of lymphocytes. Although we have 
not formally demonstrated that this gate contains exclusively 
lymphocytes and given the recent observations of aberrant 
cell population in relapsed AML patients requiring careful 
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Figure 3 Constitutive phospho and survivin expression in AML cells (n = 40) without stimulation of stem cell factor (SCF). Panel A: Phospho-protein expression of individual 
samples represented as mean fluorescence value (log transformed and subtracted from isotype control) for pAKT, p-cKIT, pERK, pFLT3, pS6Ribo, pY100, and survivin and 
classified by phenotype (1 and 2) and FAB classification (x-axis). Panel B: Summary representation of phospho-protein and survivin expression. expression of each phospho-
protein is represented as mean fluorescence after normalizing to isotype control. pAKT and pERK have lower expression than pc-KIT, pFLT3, pS6Ribo, PY100 and survivin. 
Panel C: Phospho-protein expression classified by FAB AML classification. Expression of phospho-protein and survivin expression represented as mean fluorescence level 
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flow cytometry evaluation,23 prior studies have consistently 
demonstrated that this gate contains lymphocytes in patients 
with AML.24 This careful differentiation is important in order 
to attribute the phospho-protein profile to the AML cells. In 
the future, lymphocyte staining may be necessary if phospho 
protein staining should also include the evaluation of changes 
in the lymphocyte population, such as lymphocytic leukemia. 
By using a semi-physiological stimulation for bone marrow-
derived cells with SCF, this selective stimulation of IKs in 
AML versus lymphocytes can be used to further support 
the identification of a unique phospho-protein expression 
in AML cells. The increased phospho-protein levels of pS6 
and pAKT after stimulation with SCF is consistent with a 
differential activation of AML cells (Table 3). Lymphocytes 
do not typically have receptors associated with phosphory-
lation of S6 and AKT, which in turn explains that pS6 and 
pAKT were significantly increased after SCF stimulation 
(Table 3). Such increases have been also observed in patients 
with the ITD-FLT3 mutation (Shults, personal communica-
tion). By contrast, pERK activation has been observed in 
lymphocytic lineages or in activated lymphocytes.25,26 Despite 
the possibility that pERK activation could also be found in 
lymphocytes, in this study the 11-fold increase of pERK 
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Figure 4 Constitutive phospho and survivin and expression in AML cells (n = 40) with stimulation of stem cell factor (SCF). Panel   A: Phospho-protein expression of individual 
samples represented as mean fluorescence value (log transformed and subtracted from isotype control) for pAKT, p-cKIT, pERK, pFLT3, pS6Ribo, pY100, and survivin and 
classified by phenotype (1 and 2) and FAB classification (x-axis). Panel B: Summary representation of phospho-protein and survivin expression. Expression of each phospho-
protein is represented as mean fluorescence after normalizing to isotype control. pAKT and pERK have lower expression than pc-KIT, pFLT3, pS6Ribo, PY100, and survivin. 
Panel C: Phospho-protein expression classified by FAB AML classification. Expression of phospho-protein and survivin expression represented as mean fluorescence level 
(log transformed after subtracting values of isotype control) subtypes and plotted for each FAB AML subtype. Compared to all other subtypes, M3 AML cells have lower 
pFLT3, pS6, and pY100 fluorescence.
Table 3 Comparison of phospho-protein and survivin responses 
between unstimulated and SCF-stimulated AML cells
Phospho-protein  
and survivin  
response
Fold change  
(SCF-stimulated/ 
unstimulated)
P-value (bold 
are significant 
changes)
P-AKT 8.2 0.0001
P-ckit 1.0 0.9733
P-eRK 2.2 0.02
P-FLT3 1.0 0.9481
P-S6 Ribo 6.3 0.0001
P-Y100 1.0 0.9129
Survivin 0.9 0.8019Cancer Management and Research 2009:1 58
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over lymphocytes and its increase after SCF stimulation, 
suggest that pERK was primarily activated in AML cells. 
Finally, vitality of AML blasts may influence the assess-
ment of phospho protein expression in AML blasts. This 
may be of particular importance for shipping AML samples 
from the hematology practices to the test laboratory. Prior 
to conducting this study we performed a validation study of 
cell lines and 10 primary AML samples to investigated this 
potential risk. We found that AML blasts had to be assessed 
within 24 to 48 hours after sampling in order to measure 
consistent and reproducible phospho protein levels (Shults, 
personal communication).
While recent guidelines for classifying AML recommend 
the use of the new World Health Organization (WHO) 
classification,27 the comparison of the phospho-protein 
expression to FAB AML subtypes may contribute to further 
re-fine outcome in AML patients (Table 1). Although the 
sample size in this study may be too limited to reach a final 
conclusion, in this set of data it appears that M4 and M5 
subtypes exhibit a higher phospho-protein expression than 
patients with a M3 subtype. Whether this observation is con-
sistent with previous reports suggesting that FLT3 expression 
is highest in M4 and M5 subtypes and thus is associated with 
a poor survival remains to be investigated.28
In conclusion, the present assay holds promise to detect 
pharmacodynamic changes in AML cells after treatment 
with a broadly active IK inhibitor and should be evaluated 
for its use in future clinical trials. However, the relevance of 
determining phospho protein levels as a prognostic marker 
Table 4 Comparison of overall phospho-protein and survivin 
responses between unstimulated and lymphocytes
AML subtype  
(FAB classification) 
Fold change  
(Untreated/ 
Lymphocytes)
P-value 
 
M5 12.4 0.0001
M4 7.1 0.0001
nD 3.5 0.0001
M2 3.4 0.0086
M1 2.0 0.0411
M3 1.5 0.4908
Abbreviation: ND, not defined.
A B
Response
Fold Change 
(Untreated/ 
Lymphocytes) p value
p-AKT 5,8 <0.0001
p-cKIT 3,3 <0.0001
p-ERK 11,1 <0.0001
p-FLT3 2,7 0,0001
p-S6-Ribo 3,1 <0.0001
p-Y100 3,2 <0.0001
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Figure 5 Panel A:  Comparison of phospho-protein expression in AML blasts compared to lymphocyte population. Compared to lymphocytes, the expression of phospho-proteins 
is on average at least 2-fold higher in AML blasts with peRK, pAKT, and pcKiT showing the highest difference (all responses are statistically different from 0. Since the data are 
on the log2 scale and all the means are greater than 1 indicate that that all responses are greater than 2-fold higher than the lymphocytes). Panel B: Between the phenotype 1 
and 2, phospho-protein expression ratio compared to lymphocytes is generally higher in AML phenotype 2 cells compared with phenotype 1 cells.Cancer Management and Research 2009:1
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was not the objective of this study and future prospective 
studies have to be conducted to determine its usefulness.
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